2026-08-29T14:55:28Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/149202025-04-30T12:45:14Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Vigon-Hernandez, Lorena author Sánchez-Tornero, Adrián author Rodríguez-Mora, Sara author García-Pérez, Javier author Corona de Lapuerta, Magdalena author Pérez-Lamas, Lucía author Casado-Fernández, Guiomar author Moreno, Gemma author Torres, Montserrat author Mateos, Elena author Murciano-Antón, María Aranzazu author Alcamí, José author Perez-Olmeda, Mayte author López-Jiménez, Javier author García-Gutiérrez, Valentín author Coiras, Mayte author Multidisciplinary Group Of Study Of Covid-Mgs-Covid author 2022-04-11 Oncohematological patients show a low immune response against SARS-CoV-2, both to natural infection and after vaccination. Most studies are focused on the analysis of the humoral response; therefore, the information available about the cellular immune response is limited. In this study, we analyzed the humoral and cellular immune responses in nine individuals who received chemotherapy for their oncohematological diseases, as well as consolidation with autologous stem cell transplantation (ASCT), after being naturally infected with SARS-CoV-2. All individuals had asymptomatic or mild COVID-19 and were not vaccinated against SARS-CoV-2. These results were compared with matched healthy individuals who also had mild COVID-19. The humoral response against SARS-CoV-2 was not detected in 6 of 9 oncohematological individuals prior to ASCT. The levels of antibodies and their neutralization capacity decreased after ASCT. Conversely, an enhanced cytotoxic activity against SARS-CoV-2-infected cells was observed after chemotherapy plus ASCT, mostly based on high levels of NK, NKT, and CD8+TCRγδ+ cell populations that were able to produce IFNγ and TNFα. These results highlight the importance of performing analyses not only to evaluate the levels of IgGs against SARS-CoV-2, but also to determine the quality of the cellular immune response developed during the immune reconstitution after ASCT. J Clin Med. 2022 Apr 11;11(8):2137. 10.3390/jcm11082137 2077-0383 Journal of clinical medicine 35456230 http://hdl.handle.net/20.500.12105/14920 COVID-19 SARS-CoV-2 neutralizing antibodies Autologous transplantation Cellular cytotoxicity Oncohematological disease Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection